C12N 2501/07
Heat shock proteins
C12N2501/07 (Heat shock proteins) appears on 16 US grants and 36 published applications in this corpus.
Search patents in C12N- Granted patents
- 16
- Published applications
- 36
- Assignees
- 20
- Inventors
- 63
- Latest grant
- 21 Jun 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 0 | 1 |
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 0 | 1 |
| 2007 | 1 | 0 |
| 2008 | 1 | 2 |
| 2009 | 2 | 3 |
| 2010 | 2 | 4 |
| 2011 | 1 | 1 |
| 2012 | 1 | 1 |
| 2013 | 1 | 4 |
| 2014 | 3 | 3 |
| 2015 | 0 | 1 |
| 2016 | 1 | 1 |
| 2017 | 1 | 1 |
| 2018 | 0 | 1 |
| 2019 | 0 | 1 |
| 2020 | 0 | 3 |
| 2021 | 0 | 1 |
| 2022 | 2 | 2 |
By publication year.
Recent patents
- Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer21 Jun 2022US 11,364,264 B2The General Hospital Corporation
- Methods and compositions for treating urea cycle disorders8 Mar 2022US 11,266,655 B2Camp4 Therapeutics Corporation
- Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases4 Jul 2017US 9,694,059 B2Universidad De Chile
- Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells15 Mar 2016US 9,284,591 B2Bayer HealthCare LLC
- Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells8 Jul 2014US 8,772,027 B2Bayer Pharmaceuticals Corporation
- Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of cancer13 Oct 2022US 2022/0323493 A1The General Hospital Corporation
- Methods and compositions for treating urea cycle disorders2 Jun 2022US 2022/0168316 A1Camp4 Therapeutics Corporation
- Methods and compositions for treating urea cycle disorders22 Apr 2021US 2021/0114996 A1Camp4 Therapeutics Corporation
- Methods and compositions for treating urea cycle disorders, in particular otc deficiency8 Oct 2020US 2020/0316038 A1Camp4 Therapeutics Corporation
- Ex Vivo Maintenance and Expansion of Stem Cells27 Aug 2020US 2020/0270576 A1The Regents of the University of California
Most cited
By later US patents
- Application of Hsp70 proteins15US 7,396,681 B12008
- Hsp70 peptide stimulating natural killer (NK) cell activity and uses thereof14US 7,517,948 B2Multimmune GmbH · 2009
- Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells8US 7,244,616 B2Bayer Pharmaceuticals Corporation · 2007
- Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells3US 8,192,985 B2Bayer Pharmaceuticals Corporation · 2012
- Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells3US 8,409,857 B1Bayer Pharmaceuticals Corporation · 2013